Premium
Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states
Author(s) -
Walker B D,
Singleton C B,
Bursill J A,
Wyse K R,
Valenzuela S M,
Qiu M R,
Breit S N,
Campbell T J
Publication year - 1999
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0702774
Subject(s) - herg , cisapride , pharmacology , potassium channel , torsades de pointes , chemistry , potassium channel blocker , blockade , qt interval , depolarization , potency , ic50 , medicine , biochemistry , receptor , in vitro
Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest. The cellular mechanism for these observations is high affinity blockade of I Kr (encoded by HERG). In a chronic transfection model using CHO‐K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC 50 16.4 n M at 20–22°C and 23.6 n M at 37°C). Channel inhibition exhibited time‐, voltage‐ and frequency‐dependence. In an envelope of tails test, channel blockade increased from 27±8% after a 120 ms depolarizing step to 50±4% after a 1.0 s step. These findings suggested affinity for open and/or inactivated channel states. Inactivation was significantly accelerated by cisapride in a concentration‐dependent manner and there was a small (−7 mV) shift in the voltage dependence of steady state inactivation. Channel blockade by cisapride was modulated by [K + ] o , with a 26% reduction in the potency of channel blockade when [K + ] o was increased from 1 to 10 m M . In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration. These features may have significant clinical implications with regard to the mechanism and treatment of cisapride‐induced proarrhythmia.British Journal of Pharmacology (1999) 128 , 444–450; doi: 10.1038/sj.bjp.0702774